Build a technology platform to allow more people to sing the "R&D drama"
---"Xinshengyuan" is currently operating dozens of biomedical projects, breaking through the "ten-year grind" The practice of "one drug"
Independent innovation benefits the people
Zhangjiang Biomedical Valley will turn ten this year, and hundreds of biomedical companies and research units are nurturing more than one miracle. Shanghai Xinshengyuan Pharmaceutical Research Co., Ltd., which just moved into the "Medicine Valley" last year, is one of them.
With a registered capital of 300,000 yuan, it created a miracle in the biomedical industry, which is known for its investment, time and high risks - it took less than 5 years to give birth to the "miracle boy". With more than 60 Chinese and international invention patents, 5 clinical approvals, 12 new drug applications, a universal new drug research and development platform with many links, and technology transfer centers all over Asia, international capital has to look at it with admiration.
The results of new drugs "come close to you"
The story of "it takes ten years to develop a drug" is almost commonplace for biomedical research and development. However, on the technical service platform of Zhangjiang's "Xinshengyuan", nearly 60 research projects are currently operating, and more than one new drug has entered the final "sprint" stage of research. "Recombinant human keratin growth factor-2" is expected to obtain drug certification within this year. It can promote wound healing and can also treat various refractory ulcers such as diabetic ulcers and inflammatory bowel disease. The factory building covering an area of ??80 acres on Chongming Island is waiting for this purpose. It is expected that the cumulative sales revenue will be 300 million yuan by 2008 after it is put into operation. "Recombinant human proinsulin C peptide" and "recombinant ovarian cancer unique microantibodies" are not far away from being completed. Long-term complications of diabetes, mainly diabetic nephropathy, and the ovary will encounter their "nemesis".
At the beginning of this year, 17 biomedical achievements were "married" to Pakistan, creating a contract value of more than 10 million US dollars for Zhangjiang's "new source". Iran, Egypt, Saudi Arabia, and India have also become targets of technology transfer; at the same time, core technologies from developed countries have successively "settled" here. Among them, the humanized antibody technology from France is mainly used to treat rejection after transplantation and is expected to apply for clinical trials this year; the anti-hepatitis B and AIDS drug technology from South Korea has entered the "pill arrangement" stage and is expected to start clinical trials by the end of this year and early next year. During the "Eleventh Five-Year Plan" period, "Wonder Boy" aims to complete 60 clinical trial applications and new drug declarations.
Don’t be a lonely “long-distance runner”
Looking at the roster of Zhangjiang’s “new sources”, there are only more than 100 full-time employees and nearly 60 part-time scientific consultants. Zhang Yi, director and general manager, said frankly that such special staffing is the driving force for independent innovation of the company. The fifty or sixty scientific consultants are mostly scientists from universities, research institutes and hospitals. They come with inspiration and topics to find a series of answers to preclinical, clinical and industrialization on the platform. In most "R&D dramas", Zhang Jiang's "Xinshengyuan" does not play the leading role, but has played almost all roles.
At that time, a team of 18 people started a business with three new national biotechnology first-class drugs. The original intention of Zhangjiang’s “New Source” was to become a link between industry, academia and research, and to promote the transformation of more high-tech achievements. Without funds, we survived 9 months without receiving salary; lacking experimental space, we "fighted guerrilla" in the laboratories of universities and scientific research institutes; when we received the first service "order", we regarded it as Do rare military training. With the increase in military training opportunities, Zhang Jiang's "New Generation" quickly became familiar with the full set of processes and details from basic research to industrialization, and also found an independent innovation model that suits him; instead of being a lonely long-distance runner, it is better to form a strong team Relay Team - a series of new drug research and development platforms. At present, resources such as space, equipment, consumables, etc., which account for 70% to 80% of the cost of new drug research and development, can be fully enjoyed, and the amount of direct pre-clinical investment has been reduced to 2 million yuan.
The capital "snowball" is getting bigger and bigger
If nothing unexpected happens, Shanghai Xinshengyuan Biopharmaceutical Co., Ltd. will be listed on NASDAQ in the United States in the first half of this year, becoming China's Biopharmaceutical R&D is the “first stock on the market” with an issuance market value expected to reach US$100 million.
Such a high "return" actually comes from the first "personal bonus" from the transformation of Shanghai's high-tech achievements. Five years ago, Shanghai took the lead in the country in launching the "Eighteen Regulations" on science and technology (several regulations to promote the transformation of high-tech achievements in Shanghai). Professor Song Houyan of Shanghai Medical University received a transfer of 3.04 million yuan for the transfer of "Recombinant Streptokinase for Injection" Income rewards for becoming “the first person to be distributed according to technical elements”. Ren Jun, the founder and chairman of Zhangjiang "Xinshengyuan", is the third person to complete the project, and the 300,000 yuan registered capital of Zhangjiang "Xinshengyuan" also came from this. Over the years, Zhangjiang "New Energy" has successfully promoted 7 high-tech achievement transformation projects, with a contract value of 134 million yuan - a wonderful "sequel" is now being released.
Xinmin Evening News